CEA、CYERA21-1、SCC-Ag及NSE检测在联合放化疗中的疗效评价

Clinical Evaluation of Tumor Marker in Chemotherpapy Combined with Cancurrent Radiotherapy

目的:探讨肺癌联合放化疗前后外周血中肿瘤标志物癌胚抗原(CEA)、细胞角蛋白19片段、鳞癌相关抗原(SCC-Ag)、神经元特异性烯醇化酶水平的检测及其意义。方法:采用放射免疫技术对42例肺癌患者放化疗前后4种肿瘤标志物水平进行检测,同时行胸部CT检查进行分析。结果:肺癌治疗有效组4种肿瘤标志物水平显著下降,无效组标志物水平无变化或升高;CEA对腺癌,CYERA21-1、SCC-Ag对鳞癌,NSE对小细胞癌的放化疗疗效评价有一定意义。结论:4种肿瘤标志物联合检测有助于放化疗的疗效评价。

Objective：To investigate the value of combined detection of serum CEA、SCC-Ag CYFRA21-1 and NSE markers in the patients with lung cancer befor and after chemotherapy combined with cancurrent radiotherapy.Methods：Using immunoradiometic assey,The four serum markers were measured in 42 cases of lung cancer befor and after chemotherapy combined with cancerrent radiotherapy,while the changes of CT images were analysed.Results：The Four serum markes were deareased significantly in the patients with sffective therapy,but increased or not changed in the patients withnoneffective therapy.The changes of CYERA21-1 and SCC-Ag were valuable in adenoearcinoma patients,and so did CEA in squamoous cell careinoma ones,NSE in small cell lung cancer ones.Conclusion：Combined detection of serum CEA、SCC-Ag、CYFRA21-1 and NSE markes is value in evaluating therapeutic efficacy in lung cancer patients.